Zacks: Analysts Anticipate Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Will Announce Earnings of -$0.40 Per Share

Brokerages forecast that Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSAGet Rating) will post ($0.40) earnings per share for the current quarter, Zacks reports. Two analysts have issued estimates for Kiniksa Pharmaceuticals’ earnings, with estimates ranging from ($0.52) to ($0.27). Kiniksa Pharmaceuticals reported earnings per share of ($0.72) during the same quarter last year, which indicates a positive year-over-year growth rate of 44.4%. The company is scheduled to report its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Kiniksa Pharmaceuticals will report full year earnings of ($1.82) per share for the current year, with EPS estimates ranging from ($2.05) to ($1.58). For the next fiscal year, analysts forecast that the company will post earnings of ($1.40) per share, with EPS estimates ranging from ($1.55) to ($1.25). Zacks’ EPS averages are an average based on a survey of sell-side research firms that that provide coverage for Kiniksa Pharmaceuticals.

Kiniksa Pharmaceuticals (NASDAQ:KNSAGet Rating) last released its quarterly earnings data on Tuesday, February 22nd. The company reported ($0.53) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.44) by ($0.09). The business had revenue of $18.75 million for the quarter, compared to the consensus estimate of $16.32 million.

A number of analysts have commented on KNSA shares. Bank of America cut their price objective on shares of Kiniksa Pharmaceuticals from $37.00 to $34.00 and set a “buy” rating for the company in a report on Wednesday, December 29th. Zacks Investment Research cut shares of Kiniksa Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, February 24th.

KNSA stock traded down $0.59 during mid-day trading on Monday, reaching $10.82. The company’s stock had a trading volume of 324,515 shares, compared to its average volume of 352,428. The stock has a market cap of $747.71 million, a PE ratio of -4.70 and a beta of -0.02. Kiniksa Pharmaceuticals has a fifty-two week low of $9.05 and a fifty-two week high of $17.71. The company’s 50 day moving average price is $10.43.

Several large investors have recently bought and sold shares of KNSA. Invesco Ltd. purchased a new position in shares of Kiniksa Pharmaceuticals during the 2nd quarter worth approximately $153,000. Morgan Stanley boosted its position in shares of Kiniksa Pharmaceuticals by 115.5% during the 2nd quarter. Morgan Stanley now owns 383,934 shares of the company’s stock worth $5,348,000 after purchasing an additional 205,803 shares during the period. M&T Bank Corp boosted its position in shares of Kiniksa Pharmaceuticals by 88.3% during the 3rd quarter. M&T Bank Corp now owns 20,501 shares of the company’s stock worth $234,000 after purchasing an additional 9,611 shares during the period. SG Americas Securities LLC purchased a new position in shares of Kiniksa Pharmaceuticals during the 3rd quarter worth approximately $211,000. Finally, M&G Investment Management Ltd. purchased a new position in shares of Kiniksa Pharmaceuticals during the 3rd quarter worth approximately $1,568,000. 43.01% of the stock is owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals Company Profile (Get Rating)

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

Recommended Stories

Get a free copy of the Zacks research report on Kiniksa Pharmaceuticals (KNSA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kiniksa Pharmaceuticals (NASDAQ:KNSA)

Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.